Log in
NASDAQ:MRNS

Marinus Pharmaceuticals Competitors

$11.15
+0.45 (+4.21 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.84
Now: $11.15
$12.98
50-Day Range
$7.08
MA: $8.67
$13.84
52-Week Range
$4.04
Now: $11.15
$16.28
Volume2.32 million shs
Average Volume623,707 shs
Market Capitalization$340.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2

Competitors

Marinus Pharmaceuticals (NASDAQ:MRNS) Vs. MGNX, TRIL, ICPT, MRSN, HRTX, and RCKT

Should you be buying MRNS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Marinus Pharmaceuticals, including MacroGenics (MGNX), Trillium Therapeutics (TRIL), Intercept Pharmaceuticals (ICPT), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), and Rocket Pharmaceuticals (RCKT).

MacroGenics (NASDAQ:MGNX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Institutional & Insider Ownership

95.0% of MacroGenics shares are owned by institutional investors. Comparatively, 74.5% of Marinus Pharmaceuticals shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 2.8% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

MacroGenics has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Profitability

This table compares MacroGenics and Marinus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-214.06%-72.15%-53.05%
Marinus PharmaceuticalsN/A-110.95%-74.20%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MacroGenics and Marinus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics211102.64
Marinus Pharmaceuticals00903.00

MacroGenics presently has a consensus target price of $30.8333, suggesting a potential upside of 23.19%. Marinus Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 142.15%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than MacroGenics.

Earnings and Valuation

This table compares MacroGenics and Marinus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million21.10$-151,810,000.00($3.16)-7.92
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26

Marinus Pharmaceuticals has lower revenue, but higher earnings than MacroGenics. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Summary

MacroGenics beats Marinus Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

66.6% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 74.5% of Marinus Pharmaceuticals shares are held by institutional investors. 2.8% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Trillium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.

Profitability

This table compares Trillium Therapeutics and Marinus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-236.94%-53.74%
Marinus PharmaceuticalsN/A-110.95%-74.20%

Analyst Ratings

This is a summary of recent ratings and price targets for Trillium Therapeutics and Marinus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics00403.00
Marinus Pharmaceuticals00903.00

Trillium Therapeutics presently has a consensus target price of $15.1667, suggesting a potential upside of 10.95%. Marinus Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 142.15%. Given Marinus Pharmaceuticals' higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Trillium Therapeutics.

Valuation and Earnings

This table compares Trillium Therapeutics and Marinus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.0011,206.32$-41,620,000.00($1.38)-9.91
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26

Trillium Therapeutics has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Marinus Pharmaceuticals beats Trillium Therapeutics on 6 of the 11 factors compared between the two stocks.

Intercept Pharmaceuticals (NASDAQ:ICPT) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Intercept Pharmaceuticals and Marinus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$252 million5.29$-344,680,000.00($10.89)-3.71
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26

Marinus Pharmaceuticals has lower revenue, but higher earnings than Intercept Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 74.5% of Marinus Pharmaceuticals shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Intercept Pharmaceuticals and Marinus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intercept Pharmaceuticals-119.73%-1,973.10%-47.50%
Marinus PharmaceuticalsN/A-110.95%-74.20%

Volatility and Risk

Intercept Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Intercept Pharmaceuticals and Marinus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intercept Pharmaceuticals017702.29
Marinus Pharmaceuticals00903.00

Intercept Pharmaceuticals presently has a consensus target price of $75.6087, suggesting a potential upside of 87.06%. Marinus Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 142.15%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Intercept Pharmaceuticals.

Summary

Marinus Pharmaceuticals beats Intercept Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Marinus Pharmaceuticals (NASDAQ:MRNS) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Marinus Pharmaceuticals and Mersana Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26
Mersana Therapeutics$42.12 million31.60$-28,210,000.00($0.65)-29.93

Mersana Therapeutics has higher revenue and earnings than Marinus Pharmaceuticals. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.5% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 95.7% of Mersana Therapeutics shares are held by institutional investors. 2.8% of Marinus Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Marinus Pharmaceuticals and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marinus PharmaceuticalsN/A-110.95%-74.20%
Mersana Therapeutics-4,119.91%-54.92%-43.90%

Risk and Volatility

Marinus Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Marinus Pharmaceuticals and Mersana Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marinus Pharmaceuticals00903.00
Mersana Therapeutics00503.00

Marinus Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 142.15%. Mersana Therapeutics has a consensus price target of $24.75, suggesting a potential upside of 27.22%. Given Marinus Pharmaceuticals' higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Mersana Therapeutics.

Summary

Mersana Therapeutics beats Marinus Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Marinus Pharmaceuticals (NASDAQ:MRNS) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Marinus Pharmaceuticals and Heron Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26
Heron Therapeutics$145.97 million9.09$-204,750,000.00($2.50)-5.84

Marinus Pharmaceuticals has higher earnings, but lower revenue than Heron Therapeutics. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.5% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Heron Therapeutics shares are held by institutional investors. 2.8% of Marinus Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Marinus Pharmaceuticals and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marinus PharmaceuticalsN/A-110.95%-74.20%
Heron Therapeutics-157.65%-57.52%-43.64%

Risk and Volatility

Marinus Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Marinus Pharmaceuticals and Heron Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marinus Pharmaceuticals00903.00
Heron Therapeutics01802.89

Marinus Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 142.15%. Heron Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 119.03%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Heron Therapeutics.

Summary

Marinus Pharmaceuticals beats Heron Therapeutics on 7 of the 13 factors compared between the two stocks.

Marinus Pharmaceuticals (NASDAQ:MRNS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Marinus Pharmaceuticals and Rocket Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($0.99)-11.26
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-14.60

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.5% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Rocket Pharmaceuticals shares are held by institutional investors. 2.8% of Marinus Pharmaceuticals shares are held by insiders. Comparatively, 38.8% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Marinus Pharmaceuticals and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marinus PharmaceuticalsN/A-110.95%-74.20%
Rocket PharmaceuticalsN/A-32.55%-25.42%

Risk and Volatility

Marinus Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Marinus Pharmaceuticals and Rocket Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marinus Pharmaceuticals00903.00
Rocket Pharmaceuticals00903.00

Marinus Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 142.15%. Rocket Pharmaceuticals has a consensus price target of $35.6667, suggesting a potential upside of 54.60%. Given Marinus Pharmaceuticals' higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Summary

Rocket Pharmaceuticals beats Marinus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MacroGenics logo
MGNX
MacroGenics
1.3$25.03+1.4%$1.35 billion$64.19 million-7.41Analyst Revision
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.4$13.67+0.4%$1.34 billion$120,000.00-5.56Analyst Upgrade
Increase in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$40.42+1.6%$1.33 billion$252 million-3.90
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.4$19.46+5.3%$1.33 billion$42.12 million-14.20Insider Selling
Heavy News Reporting
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.6$14.61+0.3%$1.33 billion$145.97 million-6.49
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.9$23.07+0.8%$1.27 billionN/A-13.81Analyst Report
Analyst Revision
Heavy News Reporting
Epizyme logo
EPZM
Epizyme
2.2$11.94+1.8%$1.21 billion$23.80 million-5.74
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.4$3.96+3.5%$1.19 billion$1.63 billion-2.54
Tocagen logo
TOCA
Tocagen
0.8$49.00+6.9%$1.17 billion$40,000.00-20.68
ZNTL
Passage Bio
1.7$29.02+3.8%$1.16 billionN/A0.00Lockup Expiration
STOK
Stoke Therapeutics
1.1$34.54+4.6%$1.15 billionN/A-19.19
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.1$17.68+0.2%$1.15 billion$15 million-7.22
AKRO
Akero Therapeutics
2.2$32.13+0.1%$1.11 billionN/A-15.30Heavy News Reporting
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.6$14.84+0.9%$1.09 billion$40.89 million-5.23
Innoviva logo
INVA
Innoviva
0.9$10.74+0.2%$1.09 billion$261.02 million5.21Analyst Downgrade
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.4$15.82+3.9%$1.07 billionN/A-7.19
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$20.31+0.5%$1.07 billion$392.76 million9.19
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$37.52+3.9%$1.04 billion$148.36 million-11.37
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$0.53+0.0%$1.03 billion$9.48 million-0.57Decrease in Short Interest
Heavy News Reporting
Athenex logo
ATNX
Athenex
2.1$12.39+4.7%$1.01 billion$101.23 million-8.43
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.5$22.92+4.5%$1.01 billionN/A-6.92Analyst Downgrade
PHAT
Phathom Pharmaceuticals
1.3$34.81+0.7%$1.01 billionN/A-2.49
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.5$15.72+1.2%$1.01 billion$73.41 million-3.40
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.8$40.09+6.5%$977.72 million$20.79 million-15.78Increase in Short Interest
Zogenix logo
ZGNX
Zogenix
1.6$17.50+1.5%$970.34 million$3.65 million-1.84Analyst Downgrade
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.7$43.14+3.1%$964.40 millionN/A-15.03Unusual Options Activity
ARVN
Arvinas
1.4$24.42+2.2%$958.19 million$42.98 million-10.57Increase in Short Interest
ARQT
I-Mab
1.3$25.06+1.6%$957.02 millionN/A-1.10Analyst Upgrade
Retrophin logo
RTRX
Retrophin
1.3$18.28+1.3%$930.56 million$175.34 million-8.66Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.6$19.45+7.1%$923.64 millionN/A-6.90Analyst Report
Heavy News Reporting
GOSS
Gossamer Bio
1.5$12.06+4.1%$914.49 millionN/A-3.39Analyst Report
Unusual Options Activity
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.5$43.69+0.6%$876.95 million$205.20 million546.19Analyst Downgrade
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$18.03+0.2%$856.17 million$322.36 million200.36
MORF
Morphic
1.6$26.75+6.3%$820.10 million$16.98 million-13.18
KROS
Passage Bio
1.4$40.61+1.3%$819.23 millionN/A0.00
Endo International logo
ENDP
Endo International
1.3$3.28+7.6%$752.65 million$2.91 billion-4.68Analyst Upgrade
High Trading Volume
Unusual Options Activity
Heavy News Reporting
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$19.97+2.7%$735.04 million$230,000.00-7.83Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
2.0$17.84+1.2%$721.68 million$800.40 million21.76
VBI Vaccines logo
VBIV
VBI Vaccines
1.6$3.08+5.5%$712.09 million$2.22 million-11.85
RAPT
RAPT Therapeutics
1.5$28.75+1.9%$703.48 millionN/A-2.00Analyst Downgrade
Insider Selling
Increase in Short Interest
FREQ
Frequency Therapeutics
1.5$20.50+4.4%$689.74 million$28.95 million-16.14Heavy News Reporting
PRVB
Provention Bio
2.0$12.19+2.9%$686.05 millionN/A-10.42Analyst Upgrade
Kadmon logo
KDMN
Kadmon
1.5$3.80+0.3%$650.32 million$5.09 million-4.04Analyst Report
ImmunoGen logo
IMGN
ImmunoGen
1.4$3.68+4.9%$642.32 million$82.27 million-8.56Decrease in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.5$18.49+3.9%$638.39 million$296.70 million-1,849.00Heavy News Reporting
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.31+1.6%$627.39 million$109.33 million-3.53Analyst Downgrade
Increase in Short Interest
Cara Therapeutics logo
CARA
Cara Therapeutics
1.5$12.94+3.1%$606.72 million$19.89 million-5.16
Axovant Sciences logo
AXON
Axovant Sciences
1.3$4.72+9.3%$577.16 millionN/A-2.29
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.6$41.61+1.2%$566.19 million$195.89 million-126.09Decrease in Short Interest
Heavy News Reporting
Zafgen logo
ZFGN
Zafgen
0.9$15.11+2.1%$566.17 millionN/A-15.74
This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.